Bedgebury Communications has been appointed by Novo Nordisk to work on the Levemir (insulin detemir [rDNA origin] injection) UK advertising account.
Commenting on the recent win, John Russell, Director at Bedgebury Communications, said: "We are delighted to be working with Novo Nordisk on this exciting brand and are confident that our creativity, strategic capabilities, market insight and unrivalled attitude to service will help us to deliver real value to Levemir."
Bedgebury focuses on offering a results-lead communications service, encompassing strategy development, origination and execution of creative concepts and med-ed programmes designed to address key market opportunities.
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...